Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Breast Cancer Research and Treatment

• Publication date

  1998-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1023/A:1005933815809PMID 9596482
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.

  1995cited by this paper
• Changes in biological markers after primary chemotherapy for breast cancers

  1995influential reference
• Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

  1995cited by this paper
• Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis.

  1995cited by this paper
• Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.

  1995cited by this paper
• Bcl-2: prevention of apoptosis as a mechanism of drug resistance.

  1995cited by this paper
• Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance.

  1995cited by this paper
• Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL

  1995cited by this paper
• Primary chemotherapy in surgically resectable breast cancer

  1995cited by this paper
• High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.

  1995cited by this paper
• Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells.

  1995cited by this paper
• Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.

  1995cited by this paper
• Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

  1994cited by this paper
• bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.

  1994cited by this paper
• The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma.

  1994cited by this paper
• Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.

  1994cited by this paper
• Apoptosis in breast cancer as related to histopathological characteristics and prognosis.

  1994cited by this paper
• Immunocytochemical localization of fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

  1994cited by this paper
• What does BCL-2 mean in solid tumours--friend or foe?

  1994cited by this paper
• bcl-2 protein in non-small-cell lung carcinoma.

  1994cited by this paper
• bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

  1993cited by this paper
• Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.

  1993influential reference
• Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.

  1993cited by this paper
• Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.

  1993influential reference
• bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair.

  1993cited by this paper
• Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line.

  1993cited by this paper
• bcl-2 protein in non-small-cell lung carcinoma.

  1993cited by this paper
• A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA.

  1993cited by this paper
• Bcl-2 functions in an antioxidant pathway to prevent apoptosis.

  1993cited by this paper
• Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.

  1992cited by this paper
• Apoptosis induced by anticancer drugs

  1992cited by this paper
• Induction of apoptosis in fibroblasts by c-myc protein.

  1992cited by this paper
• Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer.

  1990cited by this paper
• Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

  1990cited by this paper
• Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment.

  1987cited by this paper
• Statistical methods for assessing agreement between two methods of clinical measurement.

  1986cited by this paper
• Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

  1981cited by this paper
• Cell death: the significance of apoptosis.

  1980cited by this paper
• AKUFO AND IBARAPA.

  1965cited by this paper

• Navigating Endocrine Sensitivity Assessment in Nonmetastatic Breast Cancer Through Early On-Treatment Ki67 Understanding.

  2025cites this paper
• An Apoptosis-Related Specific Risk Model for Breast Cancer: From Genomic Analysis to Precision Medicine.

  2024cites this paper
• Prognostic significance of Ki67 during neoadjuvant chemotherapy in primary unresectable ovarian cancer

  2021influential citation
• Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR

  2019cites this paper
• Breast Cancer in Indian Women: Genetic Risk Factors and Predictive Biomarkers

  2019cites this paper
• Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor – Positive Early Breast Cancer

  2019cites this paper
• Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

  2019cites this paper
• Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014

  2018cites this paper
• Role for the transcriptional activator ZRF1 in early metastatic events in breast cancer progression and endocrine resistance

  2018cites this paper
• Streptomyces Levis ABRIINW111 Inhibits SW480 Cells Growth by Apoptosis Induction

  2018cites this paper
• P-Glycoprotein Expression in Indian Breast Cancer Patients with Reference to Molecular Subtypes and Response to Anthracycline-Based Chemotherapy—a Prospective Clinical Study from a Developing Country

  2018cites this paper
• Practical consensus recommendations regarding the management of hormone receptor positive early breast cancer in elderly women

  2018cites this paper
• Effect of p53 Codon 72 Polymorphism on Clinical Outcome in Locally Advanced Breast Cancer Patients Receiving Anthracycline Based Neoadjuvant Chemotherapy

  2017cites this paper
• Antiestrogenic Compounds and Breast Cancer

  2016cites this paper
• Early Surrogate Markers of Treatment Activity: Where Are We Now?

  2015cites this paper
• Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?

  2015cites this paper
• Complexity of Response Evaluation During Primary Systemic Therapy of Breast Cancer: Scoring Systems and Beyond-Preliminary Results.

  2015cites this paper
• Endocrine resistance in breast cancer--An overview and update.

  2015cites this paper
• Neoadjuvant endocrine therapy and window of opportunity trials: new standards in the treatment of breast cancer?

  2015cites this paper
• Glucocorticoid Receptor (NR3C1) Promoter Methylation as a Circulating Breast Cancer Biomarker and its Role in Tamoxifen Sensitivity

  2014cites this paper
• Gigantol-induced apoptosis in lung cancer cell through mitochondrial-dependent pathway

  2014cites this paper
• Automated quantitative analysis of tissue microarray of 443 patients with colorectal adenocarcinoma: low expression of Bcl-2 predicts poor survival.

  2014cites this paper
• Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review).

  2014cites this paper
• GX15-070 (Obatoclax) Induces Apoptosis and Inhibits Cathepsin D- and L–Mediated Autophagosomal Lysis in Antiestrogen-Resistant Breast Cancer Cells

  2013cites this paper
• GX 15-070 ( Obatoclax ) Induces Apoptosis and Inhibits Cathepsin Dand L – Mediated Autophagosomal Lysis in Antiestrogen-Resistant Breast Cancer Cells

  2013cites this paper
• Treatment Response to Preoperative Anthracycline-Based Chemotherapy in Locally Advanced Breast Cancer: The Relevance of Proliferation and Apoptosis Rates

  2013cites this paper
• Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study

  2012cites this paper
• Die and let live: harnessing BikDD to combat breast cancer stem cells

  2012cites this paper
• Validation of activated caspase‐3 antibody staining as a marker of apoptosis in breast cancer

  2012cites this paper
• Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women

  2012cites this paper
• Apoptotic activity in Libyan breast cancer

  2012cites this paper
• Aglepristone decreases proliferation in progesterone receptor-positive canine mammary carcinomas.

  2011cites this paper
• Cancer Therapy: Clinical Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer

  2011cites this paper
• depression levels with response to neoadjuvant chemotherapy in patients with breast cancer

  2011cites this paper
• Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.

  2011cites this paper
• celecoxib in patients with primary breast cancer

  2011cites this paper
• BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment.

  2011cites this paper
• The correlation of anxiety and depression levels with response to neoadjuvant chemotherapy in patients with breast cancer

  2011cites this paper
• Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer

  2011cites this paper
• Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.

  2011cites this paper
• Genes de proliferación y apoptosis como factores predictivos y pronósticos en el cáncer de mama: hacia una medicina personalizada Proliferation and apoptosis genes as prognostic and predictive factors in breast cancer: towards personalized medicine

  2011cites this paper
• Ki-67 biomarker in breast cancer of Indian women

  2011cites this paper
• Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer

  2010cites this paper
• Co-Inhibition of BCL-W and BCL2 Restores Antiestrogen Sensitivity through BECN1 and Promotes an Autophagy-Associated Necrosis

  2010cites this paper
• Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients.

  2010cites this paper
• Clinical implications of chemotherapy-induced tumor gene expression in human breast cancers

  2010cites this paper
• BCL-2 family function in antiestrogen-resistant breast cancer cells

  2009cites this paper
• Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells.

  2009cites this paper
• The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer

  2009cites this paper
• Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis.

  2009cites this paper
• A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study

  2009cites this paper
• XBP1, Unfolded Protein Response, and Endocrine Responsiveness

  2009cites this paper
• Research issues affecting preoperative systemic therapy for operable breast cancer.

  2008cites this paper
• Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.

  2008cites this paper
• Changes in tumour biological markers during primary systemic chemotherapy (PST).

  2008cites this paper
• Exploring the anti-tumour activity of bisphosphonates in early breast cancer.

  2008cites this paper
• Prognostic value of Bcl‐2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy

  2008cites this paper
• Description and Pre-clinical Validation of Dynamic Molecular Determinants of Sensitivity to Aromatase Inhibitors in Breast Cancer

  2008cites this paper
• Optimizing the implementation of future treatment using surrogate end-points

  2008cites this paper
• Isolated non-Hodgkin's lymphoma of the pancreas: case report and review of literature.

  2007cites this paper
• Changes in the Tumor Grade and Biological Markers in Locally Advanced Breast Cancer after Chemotherapy – Implications for a Pathologist

  2007cites this paper
• Short-term presurgical treatment for all?

  2007cites this paper
• A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.

  2007cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 221 Chemosensitivity in Breast Cancer

  2007cites this paper
• Chemosensitivity in Breast Cancer

  2007cites this paper
• Aus der Universitäts-Frauenklinik mit Poliklinik Tübingen Abteilung Allgemeine Geburtshilfe und Frauenheilkunde

  2007cites this paper
• Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer

  2006cites this paper
• NF-kappaB inhibition increases chemosensitivity to trichostatin A-induced cell death of Ki-Ras-transformed human prostate epithelial cells.

  2006cites this paper
• NF-κB inhibition increases chemosensitivity to trichostatin A-induced cell death of Ki-Ras-transformed human prostate epithelial cells

  2006cites this paper
• Serial biopsies/fine-needle aspirates and their assessment.

  2006cites this paper
• Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole

  2006cites this paper
• Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer

  2006cites this paper
• NF-k B inhibition increases chemosensitivity to trichostatin A-induced cell death of Ki-Ras-transformed human prostate epithelial cells

  2006cites this paper
• In vivo model for research of breast cancer biomarkers

  2006cites this paper
• Primary systemic therapy on local advance breast cancer, where are we going?

  2006cites this paper
• NF-kappaB inhibition radiosensitizes Ki-Ras-transformed cells to ionizing radiation.

  2005cites this paper
• Proliferation marker Ki-67 in early breast cancer.

  2005cites this paper
• 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER

  2005cites this paper
• Predictive value of biologic parameters for primary chemotherapy in operable breast cancer.

  2005cites this paper
• The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.

  2005cites this paper
• Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

  2005cites this paper
• Neoadjuvant chemotherapy in breast cancer

  2005cites this paper
• Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers

  2005cites this paper
• Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy.

  2005cites this paper
• Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin.

  2005cites this paper
• Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer.

  2005cites this paper
• NF-κB inhibition radiosensitizes Ki-Ras-transformed cells to ionizing radiation

  2005cites this paper
• The Nuclear Transcription Factor κB/bcl-2 Pathway Correlates with Pathologic Complete Response to Doxorubicin-Based Neoadjuvant Chemotherapy in Human Breast Cancer

  2005cites this paper
• Specific, pro-poptotic cell-signaling: Design of novel, recombinant targeted antitumor agents operating exclusively through modulation of cellular apoptotic events novel, targeted pro-apoptotic therapeutic agents

  2005cites this paper
• Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension

  2004cites this paper
• Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus.

  2004cites this paper
• Prognostic value of apoptosis in breast cancer (pT1-pT2). A TUNEL, p53, bcl-2, bag-1 and Bax immunohistochemical study.

  2004cites this paper
• Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors

  2004cites this paper
• Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer.

  2004cites this paper
• 99mTc-MIBI in the evaluation of breast cancer biology

  2004cites this paper
• Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study

  2004cites this paper
• Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer? -A prospective clinical study

  2004influential citation
• Expression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer

  2004influential citation
• Immediate Gene Expression Changes After the First Course of Neoadjuvant Chemotherapy in Patients with Primary Breast Cancer Disease

  2004cites this paper
• Gene Expression Profiling of 2-(4-Aminophenyl)benzothiazole-resistant MCF-7 Cells Using cDNA Microarrays.

  2004cites this paper